A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.

Demographic characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Age,Demographic characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Gender,Demographic characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Ethnicity,Demographic characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Education,Demographic characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Employment status,Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Height,Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Weight,Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Body Mass Index (BMI),Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Smoking status,Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Pre-existing Comorbidities,Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Concomitant medications for comorbidities at index date,Clinical characteristic of COVID-19 patients who have been Prescribed nirmatrelvir, ritonavir treatment and those not treated COVID antiviral: Medications used to treat COVID-19

The purpose of this study is to collect information on the:
 
 - general information of a group of people such as their age, sex
 
 - clinical information of the patients such as any other illness before having COVID 19.
 
 - the number of COVID-19 patients who meet and follow the most up to date World Health
 Organization (WHO) recommendations for medication to treat COVID-19 (such as version 14,
 published 10Nov2023) compared to Kingdom of Bahrain national recommendations
 
 - adult COVID-19 patients' health care resource use and outcomes within the 28-day period
 In adult patients with COVID-19 who have been prescribed nirmatrelvir and ritonavir
 treatment.
 
 This study will be conducted in the Kingdom of Bahrain. The study will capture information of
 the adult COVID-19 outpatients and inpatients who have been prescribed nirmatrelvir,
 ritonavir treatment and those not treated with nirmatrelvir, ritonavir.
 
 This study will have about 3000 patients treated with Paxlovid™ therapy and 1000 were not.
 The study will involve collection of patient information from medical records. The
 information collected can be either from papers or from computers.
 
 The study will include patient information of those who:
 
 - had COVID-19 infection during the study period from 16 February 2022 to 30 November
 2022.
 
 - are 18 years of age or older. This study will help to inform decision-making on use of
 Paxlovid at the national level.